A Single Site Retrospective Analysis of the Safety and Efficacy of the Amgen COMMUNITY Study

dc.contributor.advisorChaudhary, Pankaj
dc.creatorBling, Delaina
dc.date.accessioned2024-01-23T21:28:14Z
dc.date.available2024-01-23T21:28:14Z
dc.date.issued2023-05
dc.description.abstractIn 2019, a novel respiratory virus surfaced that lead to severe complications in patients and a global pandemic. One of the major issues was COVID-19 associated ARDS. The mortality rate of patients who develop ARDS from a COIVD-19 infection is 45% and at this time there are not many safe and efficacious treatments for the virus. This project exams the Amgen COMMUNITY study at a single site for efficacy and safety. The Amgen study looked at three potential treatments for COVID-19 that would hopefully lessen the occurrence and severity of ARDS; therefore, leading to a lower mortality rate. The efficacy and safety of the Amgen COMMUNITY study was evaluated retrospectively from patients data who participated in the study at the Sunbeam site.
dc.format.mimetypeapplication/pdf
dc.identifier.urihttps://hdl.handle.net/20.500.12503/32458
dc.language.isoen
dc.subjectCOVID-1
dc.subjectCOMMUNITY
dc.subjectZilucoplan
dc.subjectLanadelumab
dc.subjectApremilast
dc.subject.meshCOVID-19
dc.subject.meshRespiratory Distress Sydrome
dc.subject.meshAnti-Inflammatory Agents
dc.titleA Single Site Retrospective Analysis of the Safety and Efficacy of the Amgen COMMUNITY Study
dc.typeThesis
dc.type.materialtext
thesis.degree.departmentSchool of Biomedical Sciences
thesis.degree.disciplineClinical Research Management
thesis.degree.grantorUniversity of North Texas Health Science Center at Fort Worth
thesis.degree.nameMaster of Science

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2023_05_sbs_Bling_Delaina_practicum.pdf
Size:
346.72 KB
Format:
Adobe Portable Document Format